How comfortable is management with the Q2 2027 launch target, and what are the risks?

Management is confident in the Q2 2027 timeline, having conducted a thorough review, incorporated learnings from prototypes and integrated units, and added a design cycle to mitigate key risks. Enhanced program oversight also supports this confidence. “I think when you take all those together, based on everything we know, we think we factor that in, that the timeline of Q2 reflects the work required to deliver the product that meets our standards.”

Was the additional design cycle due to prototype performance or scale-up? How does it impact the early access program?

The design cycle was driven by internal R&D assessment of integrated machines' repeatability and manufacturing opportunities. Early access will be delayed, with sample evaluations potentially starting end of 2026/early 2027, and deployed early access in early 2027, after the design cycle is complete. “Yes, so it's definitely before the launch, but yes, I did answer that earlier. You're correct. We haven't started that yet with this design cycle that we're going through. We wouldn't expect to start that till sometime after this cycle is complete.”

How will the additional design cycle affect performance and reproducibility, and what steps are being taken to maintain prior performance expectations?

The design cycle aims to ensure all Proteus units consistently perform at a high level, above internal specifications, by implementing identified changes. It also seeks to simplify manufacturing processes and improve first-pass yield. “So what we've observed, again, in the units that we have internally is we have some instruments that really reliably perform at a very high level, meaning above our internal specifications for the product. We have other machines that are performing sort of at or a little below where that's at.”

QSI

Quantum-Si (QSI) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 13, 2026

Source: earnings call transcript

Executive summary

Quantum-Si Q2 FY26 — Proteus Launch Delayed to Q2 2027 Amidst Cost Reductions

Quantum-Si announced a delay in the Proteus launch to Q2 2027, driven by a strategic decision to incorporate an additional instrument design cycle to de-risk the platform and enhance product readiness. This timeline revision is accompanied by a 20% headcount reduction and other operating expense actions, aiming to reduce cash burn and extend the capital runway into Q4 2028. Despite the delay, management expressed strong confidence in the underlying Proteus technology, citing sufficient sequencing data from integrated units and continued progress in Recognizer development.

Highlights

Internal sequencing data from integrated Proteus units remains strong, confirming underlying technology.
Recognizer development progressing, with expectation to launch Proteus with 19 or 20 amino acid detection capability (vs. prior 18).
Identified a substantial non-human proteomics market opportunity of over $4 billion annually, based on Platinum system learnings.
Qualified over 250 institutions with stated interest in Proteus, spanning academic, biopharma, and industrial applications.
Operating expense actions expected to result in approximately $12 million in annual savings.

Concerns

Proteus launch timeline revised from end of 2026 to Q2 2027 due to an additional integrated instrument design cycle.
Revenue in Q2 2026 was $344,000, down from $591,000 in Q2 2025, reflecting limited Platinum capital purchasing.
Net loss was $23.5 million in Q2 2026.
Adjusted EBITDA was negative $21.2 million in Q2 2026.
Targeted reduction in force representing approximately 20% of total company headcount implemented to align cost structure.

Guidance & targets

Category	Target	Timeline	Confidence
Proteus launch timeline	second quarter of 2027 high materiality	Q2 · FY27	High
Amino acid detection capability at Proteus launch	either 19 or 20 amino acids medium materiality	at launch	High
Annual operating expense savings	approximately $12 million high materiality	annual	High
Capital runway	into the fourth quarter of 2028 high materiality	Q4 · FY28	High
Full-year 2026 revenue	approximately $1 million medium materiality	FY26	High
Full-year 2026 adjusted operating expenses	$98 million or less medium materiality	FY26	High
Full-year 2026 total cash usage	$93 million or less medium materiality	FY26	High

Product announcements

Product	Type	Timeline	Details
Proteus	update	launch revised to Q2 2027

Risks & headwinds

Proteus launch delay until Q2 2027

from end of 2026 to Q2 2027

Mitigation:additional integrated instrument design cycle to reduce manufacturing risk, improve system repeatability, strengthen product readiness; program leadership and governance changes; operating expense actions to align cost structure

Manufacturing complexity and risk for Proteus ongoing

more challenging and longer to get we had anticipated

Mitigation:additional design cycle to make design for manufacturability changes, aiming for more compressed build time and higher first-pass yield

Cash burn and capital runway current

net loss of $23.5 million in Q2 2026; adjusted EBITDA negative $21.2 million in Q2 2026

Mitigation:operating expense actions including 20% headcount reduction to reduce cash usage and extend runway into Q4 2028

Long lead components (e.g., GPUs) future production

not a constraint today

Mitigation:watching very closely, procuring well in advance, stockpiling to buffer potential supply issues

What to watch in Q3 FY26

Proteus instrument design cycle completion

remainder of this year

Current ongoing

Target completion of design, build, and internal testing

Why it matters

This is the key gating item for the revised Proteus launch timeline and will confirm the effectiveness of the additional design cycle in improving repeatability and manufacturability.

So we expect to work through that cycle of finalize the design, build, test, and confirm performance over the course of the remainder of this year. So that's really the big task.

Find out whether QSI delivers this. Inve re-checks your case every morning.

Q&A highlights

What was the primary driver for the Proteus launch delay, customer feedback or internal assessment?

The delay was driven by an internal assessment of machine repeatability, consistency, and manufacturing processes, not new customer feedback. The goal is to ensure high-quality manufacturing and product performance.

“It's really an internally driven assessment of where we are and the best way to get to the product with the capabilities and manufacturing quality we expect.”

asked by Scott Henry · answered by Jeffrey Hawkins

2 min read 7 chapters

Detailed narrative

Proteus Launch Timeline Revision

Quantum-Si has updated the Proteus launch timeline from the end of 2026 to the second quarter of 2027. This decision stems from an internal assessment to add an additional integrated instrument design cycle, aiming to reduce manufacturing risk, improve system repeatability, and strengthen product readiness for a positive customer experience at launch.

The company believes this approach is more responsible and capital efficient, de-risking the platform before production.

Instrument Development and Design Cycle

The additional design cycle was prompted by learnings from integrated unit testing in H1 2026, which revealed execution risks in moving directly to production. The goal is to ensure consistent high performance across all machines and simplify manufacturing processes. This cycle involves finalizing design changes, rolling them through manufacturing, building, and testing the machines, expected to be completed by the end of 2026.

Recognizer Development Progress

Progress in Recognizer development continues to meet expectations, with the internal developmental sequencing kit able to detect 17 amino acids. The revised instrument timeline provides additional time to progress further, with the company now expecting to deliver Proteus with a detection capability of either 19 or 20 amino acids at launch, an improvement from the previously anticipated 18.

Strategic Shift in Library Preparation

The company is evolving its library preparation strategy from a single generic kit to a suite of application-oriented kits. This shift is based on real-world insights from Platinum customers and aims to provide more tailored, off-the-shelf tools, making implementation more efficient and reducing customer optimization. This approach is expected to deliver a broad range of capabilities faster and with lower technical risk.

Platinum System Learnings and Market Insights

The Platinum placement program has provided valuable market and technical insights. An example includes work with a biopharma customer on AAV serotyping for gene therapy, where Platinum data modeled expected Proteus performance to meet sensitivity requirements. This application alone suggests an attractive market opportunity given over 150 companies developing AAV-based gene therapies.

Non-Human Proteomics Market Opportunity

Learnings from Platinum commercial activities have identified a substantial non-human proteomics market opportunity, estimated at over $4 billion annually. This includes pathogen research and agricultural applications, where traditional techniques are not well-suited, and a defined reference is often unavailable. The company believes Proteus's core capabilities align well with these needs.

Operating Expense Actions and Financial Strength

To preserve financial strength and align with the revised Proteus timeline, Quantum-Si announced operating expense actions, including a 20% reduction in force. These actions are designed to reduce cash burn, extend the capital runway into Q4 2028, and concentrate resources on critical Proteus readiness activities, ensuring disciplined funding over the extended timeline.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.